|
Parameter
|
Metformin group (n = 10)
|
Rimonabant group (n = 10)
|
|---|
|
Baseline
|
12 weeks
|
P-value
|
Baseline
|
12 weeks
|
P-value
|
|---|
|
IL-1β
|
86 ± 56
|
105 ± 89
|
0.17
|
85 ± 77
|
91 ± 91
|
0.32
|
|
IL-6
|
12 ± 6
|
13 ± 7
|
0.31
|
17 ± 8
|
18 ± 9
|
0.31
|
|
IL-7
|
249 ± 18
|
252 ± 31
|
0.69
|
235 ± 47
|
263 ± 49
|
0.11
|
|
IL-10
|
23 ± 32
|
27 ± 30
|
0.29
|
10 ± 6
|
10 ± 6
|
0.92
|
|
IL-12
|
203 ± 60
|
223 ± 83
|
0.11
|
201 ± 41
|
207 ± 33
|
0.50
|
|
TNF-α
|
7 ± 3
|
8 ± 4
|
0.33
|
9 ± 4
|
9 ± 4
|
0.99
|
|
MCP-1
|
294 ± 66
|
298 ± 88
|
0.80
|
279 ± 60
|
307 ± 58
|
0.6
|
|
INF-γ
|
30 ± 10
|
30 ± 9
|
0.83
|
30 ± 7
|
36 ± 9
|
0.6
|
- No difference in the inflammatory cytokine profile between metformin and rimonabant treated patients
-
IL interleukin, TNF tumour necrosis factor, MCP monocyte chemotactic protein, INF interferon
